Alternatively, another group harnessed MSC therapy combination instead with 30 mg/day of pioglitazone, a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, to treat liver fibrosis in a Phase I trial [84]. The gene discussed is PPARG; the disease is Hepatic fibrosis.